Next Generation Cancer Diagnostics Market Analysis, Size, Growth, Share, Outlook & Forecast to 2024 | Grand View Research Inc.
The global next generation cancer diagnostics market is anticipated to reach USD 11.04 billion by 2024, according to a new report by Grand View Research, Inc. Key drivers for this vertical include rising advancement in genomics and proteomics-based research coupled with increasing prevalence of oncology disorders. Rise in number of oncological research projects to elucidate tumorigenesis and the underlying mechanisms, consequently raising the demand for serial sampling, diagnosis, and therapeutic manipulation, is a growth rendering driver of this market. Further Key Findings from the Study Suggest:
The qPCR & multiplexing segment captured the largest market share in 2015 owing to the presence of a wide product portfolio serving numerous applications in oncology R&D
Next generation sequencing services and solutions for oncology applications are anticipated to be the fastest growing segment
Oncology diagnostics in biomarker discovery is expected witness growth as it subsequently facilitates drug designing and identification of novel targets against tumors
On the basis of cancer type, this vertical is segmented into lung, breast, colorectal, cervical, and other forms of cancer
Research projects to establish the therapeutic index of anticancer cytotoxic drugs are one of the key factors responsible for expected growth
North America dominated the market with respect to revenue generation in 2014 due to concerted efforts directed toward the development of next generation sequencing technology and companion diagnostics in personalized medicine
Some of the key players contributing significantly to the next generation cancer diagnostics market are Novartis AG; Cepheid; Hoffman La Roche Ltd.; PerkinElmer, Inc.; Sysmex Corporation; Abbott; Thermo Fisher Scientific, Inc.; Koninklijke Philips N.V.; Agilent Technologies; Illumina, Inc.; Genomic Health, Inc.; Qiagen; Janssen Global Services, LLC; Hologic, Inc.; Myriad Genetics, Inc.; Almac Group; Opko Health, Inc.; and GE Healthcare.
Browse Details of Report @ https://www.grandviewresearch.com/industry-analysis/nextgeneration-cancer-diagnostics-market
Grand View Research has segmented the next generation cancer diagnostics market on the basis of technology, application, cancer type, function, and region: Technology Outlook (Revenue, USD Million, 2013 - 2024)
Next Generation Sequencing
qPCR & Multiplexing
Lab-on- a- chip (LOAC) & Reverse Transcriptase-PCR (RT-PCR)
Protein Microarrays
DNA Microarrays
Application Outlook (Revenue, USD Million, 2013 - 2024)
Biomarker Development
CTC Analysis
Proteomic Analysis
Epigenetic Analysis
Genetic Analysis
Cancer Type Outlook (Revenue, USD Million, 2013 - 2024)
Lung Cancer
Breast Cancer
Colorectal Cancer
Cervical Cancer
Others
Get Sample of Report @ https://www.grandviewresearch.com/industry-analysis/next-generationcancer-diagnostics-market/request/rs1
Function Outlook (Revenue, USD Million, 2013 - 2024)
Therapeutic Monitoring
Companion Diagnostics
Prognostics
Cancer Screening
Risk Analysis
Regional Outlook (Revenue, USD Million, 2013 - 2024)
North America o
U.S
o
Europe o
Germany
o
France
Asia Pacific o
Japan
o
China
Latin America o
Canada
Brazil
Middle East & Africa o
South Africa
Table of Content
Chapter 1 Executive Summary Chapter 2 Next Generation Cancer Diagnostics Industry Outlook 2.1 Market segmentation 2.2 Market size and growth prospects, 2013 - 2024 2.3 Next generation cancer diagnostics market dynamics 2.3.1 Market driver analysis 2.3.1.1 Exponentially decreasing cost of genetic sequencing
2.3.1.2 Development of cluster chip technology and potential applications of CTC in cancer management 2.3.1.3 Rising demand for preventive medicine & companion diagnostics 2.3.1.4 Growing cancer incidence 2.3.2 Market restraint analysis 2.3.2.1 Requirement of expensive laboratory set-up for implementation of novel tests 2.4 Key Opportunities Prioritized 2.5 Industry analysis - Porter’s 2.6 Next Generation Cancer Diagnostics PESTEL Analysis Continue……… About Grand View Research, Inc.: Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.
Contact: Sherry James Corporate Sales Specialist, USA Grand View Research, Inc Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519 Email: sales@grandviewresearch.com For More Information: http://www.grandviewresearch.com